363 related articles for article (PubMed ID: 30634951)
1. Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report.
Pluvy J; Brosseau S; Stelianides S; Danel C; Nguenang M; Khalil A; Crestani B; Zalcman G; Gounant V
BMC Pulm Med; 2019 Jan; 19(1):12. PubMed ID: 30634951
[TBL] [Abstract][Full Text] [Related]
2. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
[TBL] [Abstract][Full Text] [Related]
3. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
Sari M; Saip P
J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
[TBL] [Abstract][Full Text] [Related]
4. Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
Nakahara Y; Fukui T; Shirasawa M; Harada S; Kusuhara S; Takakura A; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N; Inukai M; Sekiguchi T; Naoki K
Intern Med; 2018 Nov; 57(21):3149-3152. PubMed ID: 29877291
[TBL] [Abstract][Full Text] [Related]
5. Bilateral Testicular Metastases from Lung Adenocarcinoma Showing an Objective Response to Nivolumab: A Case Report and Review of the Literature.
Ozeki T; Fujiwara K; Shimonishi A; Nishimura J; Okawa S; Takada K; Kayatani H; Minami D; Sato K; Shibayama T
Intern Med; 2019 Nov; 58(22):3277-3282. PubMed ID: 31327829
[TBL] [Abstract][Full Text] [Related]
6. Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M
Intern Med; 2019; 58(10):1479-1484. PubMed ID: 31092773
[TBL] [Abstract][Full Text] [Related]
7. Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab.
Hisamatsu Y; Morinaga R; Watanabe E; Ohtani S; Shirao K
Am J Case Rep; 2020 Feb; 21():e920809. PubMed ID: 32018275
[TBL] [Abstract][Full Text] [Related]
8. [Can nivolumab be used safely in idiopathic pulmonary fibrosis?].
Duchemann B; Didier M; Pailler MC; Brillet PY; Kambouchner M; Uzunhan Y; Freynet O; Chouahnia K; Zelek L; Nunes H
Rev Mal Respir; 2019 Feb; 36(2):209-213. PubMed ID: 30686563
[TBL] [Abstract][Full Text] [Related]
9. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
10. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint therapy in proteinuric kidney disease.
Takenaka T; Kawai Y; Amano T
Eur J Cancer; 2018 May; 95():120-122. PubMed ID: 29530540
[No Abstract] [Full Text] [Related]
12. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma.
Shikano K; Kaneko K; Kaburaki K; Isobe K; Kawabe K; Homma S; Kawai S; Nanki T
Scand J Rheumatol; 2020 Jan; 49(1):82-83. PubMed ID: 31135242
[No Abstract] [Full Text] [Related]
14. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
[TBL] [Abstract][Full Text] [Related]
15. Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
Check JH; Check D; Poretta T
Anticancer Res; 2019 Apr; 39(4):1923-1926. PubMed ID: 30952734
[TBL] [Abstract][Full Text] [Related]
16. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
[No Abstract] [Full Text] [Related]
17. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
18. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for non-small cell lung cancer.
Vafadar S
JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
[TBL] [Abstract][Full Text] [Related]
20. [Metastatic lung adenocarcinoma. Nivolumab as second line treatment: between unresolved issues and promising future. A case report.].
Cortinovis DL
Recenti Prog Med; 2018 Mar; 109(3):197e-201e. PubMed ID: 29565054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]